Teladoc Health (NYSE:TDOC) Given New $16.00 Price Target at Stifel Nicolaus

Teladoc Health (NYSE:TDOC) had its target price decreased by Stifel Nicolaus from $21.00 to $16.00 in a research report sent to investors on Friday morning, Benzinga reports. Stifel Nicolaus currently has a hold rating on the health services provider’s stock.

TDOC has been the topic of several other reports. Cantor Fitzgerald began coverage on Teladoc Health in a report on Thursday, February 29th. They set an overweight rating and a $22.00 target price on the stock. Truist Financial cut their price objective on Teladoc Health from $23.00 to $17.00 and set a hold rating on the stock in a report on Wednesday, March 6th. Citigroup lowered their target price on Teladoc Health from $21.00 to $19.00 and set a neutral rating for the company in a research note on Wednesday, February 21st. Leerink Partnrs reaffirmed a market perform rating on shares of Teladoc Health in a research note on Monday, February 26th. Finally, Needham & Company LLC reissued a hold rating on shares of Teladoc Health in a research report on Friday. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Teladoc Health has an average rating of Hold and a consensus target price of $18.73.

Teladoc Health Stock Performance

Shares of NYSE:TDOC opened at $13.40 on Friday. The firm’s 50 day simple moving average is $14.69 and its 200 day simple moving average is $17.67. Teladoc Health has a fifty-two week low of $12.65 and a fifty-two week high of $30.41. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -9.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The firm had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. During the same quarter last year, the business posted ($0.37) earnings per share. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, sell-side analysts forecast that Teladoc Health will post -1.06 earnings per share for the current year.

Insider Activity at Teladoc Health

In related news, insider Arnnon Geshuri sold 7,500 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $15.06, for a total transaction of $112,950.00. Following the completion of the transaction, the insider now directly owns 38,470 shares of the company’s stock, valued at $579,358.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CMO Stephany Verstraete sold 7,945 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $115,361.40. Following the transaction, the chief marketing officer now directly owns 56,486 shares in the company, valued at approximately $820,176.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arnnon Geshuri sold 7,500 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $15.06, for a total transaction of $112,950.00. Following the completion of the sale, the insider now directly owns 38,470 shares in the company, valued at $579,358.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 135,441 shares of company stock valued at $2,038,251. 1.63% of the stock is owned by insiders.

Hedge Funds Weigh In On Teladoc Health

A number of institutional investors have recently bought and sold shares of TDOC. Parallel Advisors LLC increased its holdings in shares of Teladoc Health by 14.6% in the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock valued at $87,000 after purchasing an additional 515 shares during the last quarter. M&T Bank Corp grew its stake in Teladoc Health by 5.5% in the 4th quarter. M&T Bank Corp now owns 11,152 shares of the health services provider’s stock valued at $241,000 after buying an additional 584 shares during the last quarter. Van ECK Associates Corp grew its stake in Teladoc Health by 20.3% in the 4th quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock valued at $77,000 after buying an additional 606 shares during the last quarter. Arizona State Retirement System raised its holdings in Teladoc Health by 1.4% in the 3rd quarter. Arizona State Retirement System now owns 46,602 shares of the health services provider’s stock valued at $866,000 after acquiring an additional 650 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in shares of Teladoc Health by 4.3% during the third quarter. Victory Capital Management Inc. now owns 17,946 shares of the health services provider’s stock worth $334,000 after acquiring an additional 748 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.